John P. Stenbit, a director of Viasat Inc. (NASDAQ:VSAT), filed a Form 4 on September 3, 2026, reporting transactions dated September 1, 2026, involving the exercise of a stock option and a subsequent sale of common shares under a Rule 10b5-1 plan.
Director Carmen Romeo filed a Form 4 with the SEC on September 3, 2026, reporting the exercise of stock options and the sale of 5,000 shares of SEI Investments Co common stock on September 1, 2026.
Douglas A. Linebarger, Chief Legal Officer of Alkami Technology, Inc., filed a statement of changes in beneficial ownership on September 3, 2026, reporting a share disposal transaction dated September 1, 2026.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on September 3, 2026, disclosing the exercise of stock options and sale of common stock on September 2, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Prerna Sachdeva, Chief Accounting Officer of Alkami Technology, Inc., filed a Form 4 on September 3, 2026, disclosing the disposition of shares of common stock on September 1, 2026, in connection with the vesting and settlement of restricted stock units.
Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, filed a Form 4 on September 3, 2026, disclosing the exercise of stock options and the sale of resulting common stock shares pursuant to a pre-arranged Rule 10b5-1 plan.
Director Kathryn Guarini filed a Form 4 with the SEC on September 3, 2026, disclosing transactions in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) common stock dated September 2, 2026.
Richard Sun, a director of Cathay General Bancorp, filed a statement of changes in beneficial ownership on September 3, 2026, disclosing a sale of 1,000 shares of common stock on September 2, 2026.
Marion McCourt, Executive Vice President Commercial of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on September 3, 2026, reporting the sale of common stock on September 2 and September 3, 2026, pursuant to a Rule 10b5-1 plan.
Qualys, Inc. Chief Financial Officer Joo Mi Kim filed a Form 4 on September 3, 2026, disclosing the sale of 1,030 shares of common stock on September 2, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.